What is the iCMLf?

The International CML Foundation (iCMLf) is a Foundation established in 2009 by a group of hematologists with a strong interest in CML. Our mission is to improve the outcomes for patients with CML globally. We are currently registered as a charitable foundation in England and Wales, however our charter is global.

What are our aims and priorities?

The aims of the International CML Foundation (iCMLf) are to foster and coordinate global clinical and research collaborations and to improve clinical practice and disease monitoring in CML. There are numerous activities that could come within this broad vision but the initial focus is to meet the needs in CML that are not already being met by other groups, particularly those needs that are best addressed by a global organisation.

The iCMLf has three main priorities:

Improve access to world-class CML education and best practice
Increase the availability of CML testing for accurate diagnosis and monitoring. Through this we can increase access to the best possible therapies
Provide an online, global communication network for physicians and scientists working with CML

All our activities improve the lives of people with CML in the areas we reach. The ultimate vision of the iCMLf is that through the work to prevent and cure CML we can eradicate the disease.

What are our guiding principles?

A focus on chronic myeloid leukemia and related disorders
A truly independent not-for-profit foundation
Collaboration with, but independence from, the pharmaceutical industry
A global foundation with broad representation from all geographic regions
Priorities and policies determined by hematologists and scientists involved in CML research and patient care
Close consultation and cooperation with CML patient groups
Active collaborations with key national and regional leukemia groups

Who is the iCMLf for?

Everybody with an interest in CML! However, while we collaborate closely with CML patient groups, our primary goal is to assist physicians and scientists managing and researching CML.

How is the iCMLf governed and financed?

The iCMLf has:

A Board of Directors
A Scientific Advisory Board - including representation of patient advocacy groups
36 National Representatives
Supporters

Professor Qian JIANG, M.D.

Professor of International Medicine

Peking University People’s Hospital

Peking University Institute of Hematology

China

Medical education

1984-1990: M.D. Peking University Health Science Center

Clinical history

2017 - present: Chief Physician and Professor of Internal Medicine, Peking University People's Hospital, Peking University Institute of Hematology
2010 - 2017: Chief Physician and Associate Professor of Internal Medicine, Peking University People's Hospital, Peking University Institute of Hematology
2004 - 2010: Associate Chief Physician of Internal Medicine, Peking University People's Hospital, Peking University Institute of Hematology
1996 - 2004: Attending Doctor of Internal Medicine, Peking University People's Hospital, Peking University Institute of Hematology
1990 - 1996: Resident Physician of Internal Medicine, Peking University People's Hospital, Peking University Institute of Hematology

Research interests

Clinical research of CML, MPN, AML, ALL, and CLL

Professor Susanne Saußele, MD

Head, CML Excellence Center

III. Medizinische Klinik, Hematology and Oncology
University of Mannheim

Mannheim, Germany

Susanne Saußele studied medicine at the University of Heidelberg and specialized in Internal Medicine and Hematology/Oncology. She completed her thesis in the laboratory of Prof Dr Hehlmann and made her habilitation in Internal Medicine in 2013. In 2017, she was appointed as Professor of the University of Heidelberg. Currently, she is the leader of the CML Excellence Center in Mannheim including the molecular laboratory and the Study Centre of the German CML Study Group. She is acting as chief resident of the policlinic at the III. Med. Klinik, Medizinische Fakultät Mannheim, University of Heidelberg. Prof Saußele is also active as a project leader in EUTOS (European treatment and Outcome Study of CML) and in the E-MPN network (European network for MPN)and as active member in the ELN CML Working Party. Additionally she is member of the Scientific Program Committee of EHA.

Languages spoken: German, English

Dr Syed Owais Ali, MD
(Rawalpindi, Pakistan)

'I’m very lucky to have the opportunity to come to this conference. I have learned a lot by listening to the presentations and by interacting with people from other countries and from other universities and I now have the full picture in my mind.

Back home in my country I will be sharing everything that I have seen and learned here and this will help us to treat our CML patients in the right way and to better serve our patients. (Dr Owais Ali, Pakistan)

034 ESH CML 2017 Kopie

Syed Owais Ali’s attendance at the John Goldman Conference on CML in Estoril in 2017 was supported by the iCMLf Goldman Fund. At a ceremony shortly after the opening of the conference, he received a certificate from the iCMLf chairman, Professor Tim Hughes.